Reviewer's report

Title: Understanding Side Effects of Therapy for Myasthenia Gravis and their Impact on Daily Life

Version: 0 Date: 07 May 2019

Reviewer: Hiroyuki Murai

Reviewer's report:

This paper is unique because side effects of treatments of MG are listed based on patients' descriptions. This will shed light on under-recognized side effects and the hampered QOL in MG patients. There are several points to be cleared.

1. In Phase 1, fourteen adult generalized MG patients were recruited. Authors should comment how these 14 patients were selected.

2. Did Phase 2 patients consist of generalized MG only? Were some ocular MG included? Table 3 shows that only 41.7% of the Phase 2 patients received oral corticosteroids. This percentage is rather low in the generalized MG group.

3. Differences of MG type and duration of illness alters the intensity of treatments. Is there any MG-related demographic data such as accompaniment of thymomas, autoantibodies and duration of illness, postintervention status, etc?

4. In Table 4, there are side effect statements such as "muscle weakness", "double vision", and "fatigue". Why are these considered as side effects and not MG symptoms?

5. In page 12, lines 5-8, authors describe several conditions as serious side effects (blood clots, aseptic meningitis, sepsis, pneumonia, pleural edema, fluid in the heart, allergic/anaphylactic reactions, or internal bleeding). However, in Table 4, I can only find "blood clots" and "aseptic meningitis" and can't find the rest of them.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
Yes

**Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?**
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

**Quality of written English**
Please indicate the quality of language in the manuscript:

Acceptable

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments
which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal